PRIOR AUTHORIZATION CRITERIA

BRAND NAME KYPROLIS (Generic) (carfilzomib)

Status: CVS Caremark Criteria MDC
Type: Initial Prior Authorization Ref #817-A

FDA-APPROVED INDICATIONS¹

- Kyprolis in combination dexamethasone or with lenalidomide plus dexamethasone is indicated for the treatment of
 patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
- Kyprolis is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who
 have received one or more prior lines of therapy.

Compendial Uses²

Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma

CRITERIA FOR APPROVAL						
1	Does the patient have a diagnosis of multiple myeloma? [If yes, no further questions.]	Yes	No			
2	Does the patient have a diagnosis of Waldenstrom's macroglobulinemia/ lymphoplasmacytic lymphoma?	Yes	No			

Guidelines for Approval						
Duration of	of Approval	12 Months				
Set 1: Multi	ple myeloma	Set 2: Waldenström's macroglobulinemia/ lymphoplasmacytic lymphoma				
Yes to question(s)	No to question(s)	Yes to question(s)	No to question(s)			
1	None	2	1			

Mapping Instructions					
	Yes	No			
1.	Approve, 12 months	Go to 2			
2.	Approve, 12 months	Deny			

RATIONALE

These criteria meet the Medicare Part D definition of a medically accepted indication. This definition includes uses which are approved by the FDA or supported by a citation included, or approved for inclusion, in one of the Medicare approved compendia.

The intent of the criteria is to ensure that patients follow selection elements noted in labeling and/or practice guidelines in order to decrease the potential for inappropriate utilization.

REFERENCES

- 1. Kyprolis [package insert]. Thousand Oaks, CA: Onyx Pharmaceuticals, Inc.; October 2019.
- 2. The NCCN Drugs & Biologics Compendium 2018 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed October 16, 2019.
- 3. The NCCN Clinical Practice Guidelines in Oncology Multiple Myeloma (Version 1.2019) 2018 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed October 16, 2019.

Kyprolis 817-A MDC 2021.docx

© 2020 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



The NCCN Clinical Practice Guidelines in Oncology Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma (Version 2.2019) 2018 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed September 17, 2018.

DOCUMENT HISTORY


Specialty Clinical Development (KP) 07/2012 Written:

Revised:

07/2018 (CMS), BI 07/2019 (CMS), CM 07/2020 (CMS)

Reviewed: CDPR/DR 07/2012, SES 4/2014, 03/2015, MC 11/2015, SD 11/2016, AM 10/2017, DNC 10/2018, MMF 10/2019

08/2012, 07/2014, 06/2015, 01/2016, 12/2016, 12/2017, 11/2018, 01/2020 External Review:



manufacturers that are not affiliated with CVS Caremark.

© 2020 CVS Caremark. All rights reserved.



This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written